UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-37798 Selecta Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 26-1622110 (I.R.S. Emp ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-37798 (Address of principal executive offices) (Zip Code) (617) 923-1400 (Registrant's telephone number, including area cod ...

Selecta Biosciences, Inc. (SELB) Q2 2021 Earnings Conference Call August 12, 2021 8:30 AM ET Company Participants Kristen Baldwin - Chief People Officer Carsten Brunn - President and CEO Takashi Kishimoto - Chief Scientific Officer Peter Traber - Chief Medical Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Raju Prasad - William Blair John Newman - Canaccord Dan Clark - Mizuho Securities Yun Zhong - BTIG Gil Blum - Needham & Company Boobalan Pachaiyappan - H.C. Wainwright Operator Go ...

O ရှဲ Selecta… Biosciences Corporate Presentation May 2021 SELB Nasdaq Safe harbor / disclaimer Any statements in this presentation about the future expectations, plans and prospects of Selecta Biosciences, Inc. ("the company"), including without limitation, statements regarding the progress of the clinical development of SEL-212, the anticipated timing of the head-to-head trial comparing SEL-212 and pegloticase and related data readouts, the potential of ImmTOR™ to reduce AAV vector immunogenicity and enab ...

Selecta Biosciences, Inc. (SELB) Q1 2021 Earnings Conference Call May 13, 2021 8:30 AM ET Company Participants Brad Dahms - Chief Financial Officer Carsten Brunn - President and Chief Executive Officer Peter Traber - Chief Medical Officer Takashi Kishimoto - Chief Scientific Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Raju Prasad - William Blair John Newman - Canaccord Difei Yang - Mizuho Securities Chad Messer - Needham & Company Boobalan Pachaiyappan - H.C. Wainwright Ben Port ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-37798 Selecta Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 26-1622110 (I.R.S. Employe ...

O ရှဲ Selecta… Biosciences Corporate Presentation April 2021 SELB Nasdaq Safe harbor / disclaimer Any statements in this presentation about the future expectations, plans and prospects of Selecta Biosciences, Inc. ("the company"), including without limitation, statements regarding the progress of the clinical development of SEL-212, the anticipated timing of the head-to-head trial comparing SEL-212 and pegloticase and related data readouts, the potential of ImmTOR™ to reduce AAV vector immunogenicity and en ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to ____ Commission file number: 001-37798 Selecta Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 26-1622110 (State or other jurisdicti ...

Selecta Biosciences, Inc. (SELB) Q4 2020 Earnings Conference Call March 11, 2021 8:30 AM ET Company Participants Brad Dahms - CFO Carsten Brunn - President and CEO Peter Traber - CMO Takashi Kishimoto - Chief Scientific Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Raju Prasad - William Blair John Newman - Canaccord Difei Yang - Mizuho Securities Chad Messer - Needham & Company Boobalan Pachaiyappan - H.C. Wainwright Operator Good morning, and welcome to the Selecta Biosciences Fou ...

Selecta Biosciences, Inc. (SELB) Q3 2020 Earnings Conference Call November 5, 2020 8:30 AM ET Company Participants Brad Dahms - Chief Financial Officer Carsten Brunn - President and Chief Executive Officer Peter Traber - Chief Medical Officer Takashi Kishimoto - Chief Scientific Officer Conference Call Participants John Newman - Canaccord Genuity Corp. Kristen Kluska - Cantor Fitzgerald & Co. Raju Prasad - William Blair & Company, LLC Daniel Clark - Mizuho Securities USA LLC Operator Good morning and welcom ...